Showing results (131-140 of 141) with videos related to
Sort By:
Pageof 15
Cancer Immunology Research|July 1, 2024
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLsBowen Dong, Nataša Obermajer, Takemasa Tsuji, et al.The American Journal of Dermatopathology|March 20, 2026
Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of MelanomaHelana Ghali, Ayah N Al-Bzour, Aleena Boby, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.Cancer Research|October 19, 2007
Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunityYutaro Nakamura, Payal Watchmaker, Julie Urban, et al.Cell Death and Differentiation|May 20, 2021
RGS5-TGFβ-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growthShayani Dasgupta, Tithi Ghosh, Jesmita Dhar, et al.Oncoimmunology|July 7, 2017
Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironmentAliyah M Weinstein, Lu Chen, Emily A Brzana, et al.Immunological Investigations|September 29, 2012
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escapePeter A Cohen, Jennifer S Ko, Walter J Storkus, et al.Journal for Immunotherapy of Cancer|January 25, 2022
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primaryAhmad A Tarhini, Sandra J Lee, Aik-Choon Tan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2025
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk MelanomaAhmad A Tarhini, Alyssa Obermayer, Sandra J Lee, et al.Journal for Immunotherapy of Cancer|November 13, 2024
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomasLilit Karapetyan, Aofei Li, Danielle Vargas De Stefano, et al.Pageof 15